Rosetta Genomics (Rosetta Genomics) ROC % : -203.71% (As of Jun. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Rosetta Genomics's annualized return on capital (ROC %) for the quarter that ended in Jun. 2017 was -203.71%.

As of today (2024-05-24), Rosetta Genomics's WACC % is 0.00%. Rosetta Genomics's ROC % is 0.00% (calculated using TTM income statement data). Rosetta Genomics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Rosetta Genomics ROC % Historical Data

The historical data trend for Rosetta Genomics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics ROC % Chart

Rosetta Genomics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

ROC %

Get a 7-Day Free Trial

-534.56

-290.12

-173.01

-204.17

-323.09

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
ROC %	Get a 7-Day Free Trial															-289.18	-254.16	-315.80	-564.63	-203.71

Rosetta Genomics ROC % Calculation

Rosetta Genomics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2016 is calculated as:

	ROC % (A: Dec. 2016 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2015 )	+	Invested Capital (A: Dec. 2016 ))	/ count )
=	-15.664 * ( 1 - 0.21% )	/	( (7.173	+	2.503)	/ 2 )
=	-15.6311056	/	4.838
=	-323.09 %

where

	Invested Capital		(A: Dec. 2015 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	22.423	-	2.803	-	( 12.447	-	max(0, 2.803	-	19.37	+	12.447	))
=	7.173

	Invested Capital		(A: Dec. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.961	-	3.749	-	( 6.163	-	max(0, 3.804	-	9.513	+	6.163	))
=	2.503

Rosetta Genomics's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2017 is calculated as:

	ROC % (Q: Jun. 2017 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2016 )	+	Invested Capital (Q: Jun. 2017 ))	/ count )
=	-5.484 * ( 1 - 0% )	/	( (2.503	+	2.881)	/ 2 )
=	-5.484	/	2.692
=	-203.71 %

where

	Invested Capital		(Q: Dec. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.961	-	3.749	-	( 6.163	-	max(0, 3.804	-	9.513	+	6.163	))
=	2.503

	Invested Capital		(Q: Jun. 2017 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.207	-	2.001	-	( 1.325	-	max(0, 2.714	-	5.68	+	1.325	))
=	2.881

Note: The Operating Income data used here is four times the quarterly (Jun. 2017) data.

Rosetta Genomics (OTCPK:ROSGQ) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Rosetta Genomics's WACC % is 0.00%. Rosetta Genomics's ROC % is 0.00% (calculated using TTM income statement data). Rosetta Genomics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Rosetta Genomics ROC % Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (Rosetta Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Plaut Street, Science Park, Rehovot, ISR, 76706

Website

http://www.rosettagenomics.com

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Executives

Sabby Management, Llc	10 percent owner	115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd.	10 percent owner	C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458

Rosetta Genomics (Rosetta Genomics) Headlines

From GuruFocus

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

By gurufocus • 12-09-2008